Lyra Therapeutics is a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. Building on expertise in materials science, drug development and formulation, Lyra has developed proprietary technology that is designed to deliver medicines directly precisely and consistently to the affected tissue for sustained periods with a single administration. Our product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, in-office procedure and intended to deliver up to six months of continuous mometasone furoate drug therapy to the sinonasal passages for the treatment of CRS.
External link for Lyra Therapeutics
or
480 Arsenal St
Watertown, Massachusetts 02472, US
Lyra Therapeutics reposted this
Today we announced that we will suspend further development of LYR-210, the Company’s lead product candidate for the treatment of chronic rhinosinusitis (CRS). Our priority moving forward is to evaluate and explore strategic alternatives to advance LYR-210 for the potential benefit of patients. https://lnkd.in/eR55U-ZN
Today we announced that we will suspend further development of LYR-210, the Company’s lead product candidate for the treatment of chronic rhinosinusitis (CRS). Our priority moving forward is to evaluate and explore strategic alternatives to advance LYR-210 for the potential benefit of patients. https://lnkd.in/eR55U-ZN
Today, we announced our Q3 2025 Financial Results and provided a corporate update. https://lnkd.in/e3gQjVsp
Today we announce our clinical plan for LYR-210 and an upcoming late-breaking oral presentation at the Annual Meeting of the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), taking place October 11-14 in Indianapolis. https://lnkd.in/evJ6ZDxP